Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy

 
• By Derrick Gingery
Eye
The advisory committee voted that efficacy outweighed netarsudil's safety issues.

More from US FDA Performance Tracker

More from Regulatory Trackers